郑州微飒生物科技有限责任公司 咨询热线：0371-88821766
行业动态

行业动态

追踪行业前沿，洞察产业趋势

药效评价Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.

期刊：Neuropharmacology发表年份：2014作者：Faik Imeri; Daniel Fallegger; Aleksandra Zivkovic; Stephanie Schwalm; Gaby Enzmann; Kira Blankenbach; Dagmar Meyer zu Heringdorf; Thomas Homann; Burkhard Kleuser; Josef Pfeilschifter; Britta Engelhardt; Holger Stark; Andrea Huwiler
阅读更多 →

药效评价Characteristics of TRK-130 (Naltalimide), a novel opioid ligand, as a new therapeutic agent for overactive bladder.

期刊：The Journal of pharmacology and experimental therapeutics发表年份：2014作者：Morihiro Fujimura; Naoki Izumimoto; Shinobu Momen; Satoru Yoshikawa; Ryosuke Kobayashi; Sayoko Kanie; Mikito Hirakata; Toshikazu Komagata; Satoshi Okanishi; Tadatoshi Hashimoto; Naoki Yoshimura; Koji Kawai
阅读更多 →

药效评价Analysis of functional selectivity through G protein-dependent and -independent signaling pathways at the adrenergic α(2C) receptor.

期刊：Brain research bulletin发表年份：2014作者：Dalma Kurko; Zoltán Kapui; József Nagy; Balázs Lendvai; Sándor Kolok
阅读更多 →

药效评价Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.

期刊：ACS chemical neuroscience发表年份：2014作者：Michael Bubser; Thomas M Bridges; Ditte Dencker; Robert W Gould; Michael Grannan; Meredith J Noetzel; Atin Lamsal; Colleen M Niswender; J Scott Daniels; Michael S Poslusney; Bruce J Melancon; James C Tarr; Frank W Byers; Jürgen Wess; Mark E Duggan; J
阅读更多 →